MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 529120 | Name: LFF 571

Description:

WARNING: This product is for research use only, not for human or veterinary use.

LFF 571 is a protein-synthesizing GTPase (Elongation Factor) inhibitor potentially for the treatment of clostridial infection.

Chemical Structure

LFF 571
LFF 571
CAS#1160959-55-6

Theoretical Analysis

MedKoo Cat#: 529120

Name: LFF 571

CAS#: 1160959-55-6

Chemical Formula: C60H63N13O13S6

Exact Mass: 1365.2993

Molecular Weight: 1366.60

Elemental Analysis: C, 52.73; H, 4.65; N, 13.32; O, 15.22; S, 14.08

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
LFF-571; LFF571; LFF 571
IUPAC/Chemical Name
4-(((4-carboxybutyl)(2-((12Z,22Z,42Z,82Z,122Z,7S,11S,18S)-18-((S)-hydroxy(phenyl)methyl)-11-isopropyl-125-(methoxymethyl)-85-methyl-7-(2-(methylamino)-2-oxoethyl)-5,9,13,16-tetraoxo-6,10,14,17-tetraaza-1(4,2),2,4,8,12(2,4)-pentathiazola-3(2,3)-pyridinacyclooctadecaphane-36-yl)thiazol-4-yl)carbamoyl)oxy)cyclohexane-1-carboxylic acid
InChi Key
GNLYKLDXQZHYTR-QWSGWXDSSA-N
InChi Code
InChI=1S/C60H63N13O13S6/c1-28(2)44-58-72-47(39(92-58)23-85-5)51(80)62-22-42(75)69-48(49(78)30-11-7-6-8-12-30)57-67-38(26-89-57)55-65-36(24-88-55)46-33(53-66-37(25-87-53)50(79)64-35(21-41(74)61-4)56-71-45(29(3)91-56)52(81)70-44)18-19-34(63-46)54-68-40(27-90-54)73(20-10-9-13-43(76)77)60(84)86-32-16-14-31(15-17-32)59(82)83/h6-8,11-12,18-19,24-28,31-32,35,44,48-49,78H,9-10,13-17,20-23H2,1-5H3,(H,61,74)(H,62,80)(H,64,79)(H,69,75)(H,70,81)(H,76,77)(H,82,83)/t31?,32?,35-,44-,48-,49-/m0/s1
SMILES Code
CC1=C2C(N[C@@H](C(C)C)C3=NC(C(NCC(N[C@@H]([C@@H](O)C4=CC=CC=C4)C5=NC(C6=NC(C7=C(C8=NC(C(N[C@@H](CC(NC)=O)C(S1)=N2)=O)=CS8)C=CC(C9=NC(N(C(OC%10CCC(C(O)=O)CC%10)=O)CCCCC(O)=O)=CS9)=N7)=CS6)=CS5)=O)=O)=C(COC)S3)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
LFF-571 is an orally active semisynthetic thiopeptide antibiotic.
In vitro activity:
LFF571 inhibits bacterial protein synthesis by interacting with elongation factor Tu (EF-Tu) and interrupting complex formation between EF-Tu and aminoacyl-tRNA. LFF571 led to strain-dependent effects on toxin production, including decreased toxin levels after treatment with subinhibitory concentrations, and more rapid declines in toxin production than in inhibition of colony formation. Reference: Antimicrob Agents Chemother. 2015 Feb;59(2):1252-7. https://pubmed.ncbi.nlm.nih.gov/25512411/
In vivo activity:
In vivo efficacy of LFF571 was compared to vancomycin in a hamster model of C. difficile infection (CDI). Further analysis of the pooled data indicated that the survival benefit of LFF571 treatment at 5 mg/kg compared to vancomycin at 20 mg/kg was due primarily to a decrease in the risk of recurrence after end of treatment. Overall, LFF571 was more efficacious at the end of the study, at a lower dose, and with fewer recurrences, than vancomycin in the hamster model of CDI. Reference: Antimicrob Agents Chemother. 2012 Aug;56(8):4459-62. https://pubmed.ncbi.nlm.nih.gov/22644020/

Preparing Stock Solutions

The following data is based on the product molecular weight 1,366.60 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Sachdeva M, Leeds JA. Subinhibitory concentrations of LFF571 reduce toxin production by Clostridium difficile. Antimicrob Agents Chemother. 2015 Feb;59(2):1252-7. doi: 10.1128/AAC.04436-14. Epub 2014 Dec 15. PMID: 25512411; PMCID: PMC4335859. 2. Leeds JA, Sachdeva M, Mullin S, Barnes SW, Ruzin A. In vitro selection, via serial passage, of Clostridium difficile mutants with reduced susceptibility to fidaxomicin or vancomycin. J Antimicrob Chemother. 2014 Jan;69(1):41-4. doi: 10.1093/jac/dkt302. Epub 2013 Jul 25. PMID: 23887866. 3. Trzasko A, Leeds JA, Praestgaard J, Lamarche MJ, McKenney D. Efficacy of LFF571 in a hamster model of Clostridium difficile infection. Antimicrob Agents Chemother. 2012 Aug;56(8):4459-62. doi: 10.1128/AAC.06355-11. Epub 2012 May 29. PMID: 22644020; PMCID: PMC3421564.
In vitro protocol:
1. Sachdeva M, Leeds JA. Subinhibitory concentrations of LFF571 reduce toxin production by Clostridium difficile. Antimicrob Agents Chemother. 2015 Feb;59(2):1252-7. doi: 10.1128/AAC.04436-14. Epub 2014 Dec 15. PMID: 25512411; PMCID: PMC4335859. 2. Leeds JA, Sachdeva M, Mullin S, Barnes SW, Ruzin A. In vitro selection, via serial passage, of Clostridium difficile mutants with reduced susceptibility to fidaxomicin or vancomycin. J Antimicrob Chemother. 2014 Jan;69(1):41-4. doi: 10.1093/jac/dkt302. Epub 2013 Jul 25. PMID: 23887866.
In vivo protocol:
1. Trzasko A, Leeds JA, Praestgaard J, Lamarche MJ, McKenney D. Efficacy of LFF571 in a hamster model of Clostridium difficile infection. Antimicrob Agents Chemother. 2012 Aug;56(8):4459-62. doi: 10.1128/AAC.06355-11. Epub 2012 May 29. PMID: 22644020; PMCID: PMC3421564.
1: Tran MC, Claros MC, Goldstein EJ. Therapy of Clostridium difficile infection: perspectives on a changing paradigm. Expert Opin Pharmacother. 2013 Dec;14(17):2375-86. doi: 10.1517/14656566.2013.838218. Review. PubMed PMID: 24053182.

View History

Dibrospidium Free Base

Dibrospidium Free Base